Stocks · News reference

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Sep 17, 2026, 8:31 AMRishabh Mishra

As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncOct 7, 2026, 1:00 PMNa
Optimi Health to Present at the ThinkEquity Conference
Optimi Health Corp., a commercial-stage pharmaceutical manufacturer of psychedelic drug products, announced its participation in the ThinkEquity Conference on October 15, 2026, in New York City. Management will present a corporate overview and meet with investors. The company is a Health Canada-licensed manufacturer producing GMP-grade MDMA and psilocybin products for mental health therapies.
OPTH
BenzingaSep 23, 2026, 1:03 PMBenzinga Newsdesk
Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion
CSE:OPTI OPTH
BenzingaSep 16, 2026, 12:27 PMBenzinga Newsdesk
Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027
The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police,
OPTH